Identification of point mutations in the alpha-galactosidase A gene in classical and atypical hemizygotes with Fabry disease
- PMID: 2171331
- PMCID: PMC1683686
Identification of point mutations in the alpha-galactosidase A gene in classical and atypical hemizygotes with Fabry disease
Abstract
Efforts were directed to identify the specific mutations in the alpha-galactosidase A (alpha-Gal A) gene which cause Fabry disease in families of Japanese origin. By polymerase-chain-reaction-amplification of DNA from reverse-transcribed mRNA and genomic DNA, different point mutations were found in two unrelated Fabry hemizygotes. A hemizygote with classic disease manifestations and no detectable alpha-Gal A activity had a G-to-A transition in exon 1 (codon 44) which substituted a termination codon (TAG) for a tryptophan codon (TGG) and created an NheI restriction site. This point mutation would predict a truncated alpha-Gal A polypeptide, consistent with the observed absence of enzymatic activity and a classic Fabry phenotype. In an unrelated Japanese hemizygote who had an atypical clinical course characterized by late-onset cardiac involvement and significant residual alpha-Gal activity, a G-to-A transition in exon 6 (codon 301) resulted in the replacement of a glutamine for an arginine residue. This amino acid substitution apparently altered the properties of the enzyme such that sufficient enzymatic activity was retained to markedly alter the disease course. Identification of these mutations permitted accurate molecular heterozygote diagnosis in these families.
Similar articles
-
Nature and frequency of mutations in the alpha-galactosidase A gene that cause Fabry disease.Am J Hum Genet. 1993 Dec;53(6):1186-97. Am J Hum Genet. 1993. PMID: 7504405 Free PMC article.
-
Fabry disease: twenty-two novel mutations in the alpha-galactosidase A gene and genotype/phenotype correlations in severely and mildly affected hemizygotes and heterozygotes.J Investig Med. 2000 Jul;48(4):227-35. J Investig Med. 2000. PMID: 10916280
-
Point mutation in the alpha-galactosidase A gene of atypical Fabry disease with only nephropathy.Clin Nephrol. 1996 May;45(5):289-94. Clin Nephrol. 1996. PMID: 8738659
-
Fabry disease: twenty novel alpha-galactosidase A mutations causing the classical phenotype.J Hum Genet. 2001;46(4):192-6. doi: 10.1007/s100380170088. J Hum Genet. 2001. PMID: 11322659 Review.
-
[alpha-Galactosidase gene mutation and its expression product in Fabry disease (alpha-galactosidase deficiency)].Rinsho Byori. 1997 Feb;45(2):127-35. Rinsho Byori. 1997. PMID: 9120996 Review. Japanese.
Cited by
-
Acceleration of the Deamination of Cytosine through Photo-Crosslinking.Curr Issues Mol Biol. 2023 May 29;45(6):4687-4700. doi: 10.3390/cimb45060298. Curr Issues Mol Biol. 2023. PMID: 37367047 Free PMC article.
-
Fabry disease: correlation between structural changes in alpha-galactosidase, and clinical and biochemical phenotypes.Hum Genet. 2005 Aug;117(4):317-28. doi: 10.1007/s00439-005-1300-5. Epub 2005 May 28. Hum Genet. 2005. PMID: 15924232
-
Monitoring the clinical and biochemical response to enzyme replacement therapy in three children with Fabry disease.Eur J Pediatr. 2004 Oct;163(10):595-603. doi: 10.1007/s00431-004-1484-z. Eur J Pediatr. 2004. PMID: 15243806
-
Ventricular tachycardia: a presentation of Fabry disease case report.Eur Heart J Case Rep. 2018 Dec 22;3(1):yty154. doi: 10.1093/ehjcr/yty154. eCollection 2019 Mar. Eur Heart J Case Rep. 2018. PMID: 31020230 Free PMC article.
-
A carboxy-terminal truncation of human alpha-galactosidase A in a heterozygous female with Fabry disease and modification of the enzymatic activity by the carboxy-terminal domain. Increased, reduced, or absent enzyme activity depending on number of amino acid residues deleted.J Clin Invest. 1996 Oct 15;98(8):1809-17. doi: 10.1172/JCI118981. J Clin Invest. 1996. PMID: 8878432 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases